Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Feb 7;13(5):354–361. doi: 10.1097/ADM.0000000000000505

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Addiction Medicine.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0

PMC Copyright notice

Doses reflect the average daily dose. Patients received up to 3 doses per day, maximum daily dose allowed was 1000 mg of DAM or 500 mg of HDM. Treatments were delivered double blind and prescribed in DAM equivalents in a 2:1 ratio DAM:HDM. (A) Mean daily dose of injectable hydromorphone (HDM) and diacetylmorphine (DAM) received in the SALOME trial. Data reflect the first 6 months of treatment in the SALOME trial. (B) Histogram of average dose received in HDM and DAM in the SALOME clinical trial. Data reflect the first 6 months of treatment in the SALOME trial, excluding the first 30 days (dose adjustment period).